Aptorum Group Announces Pricing of $9.0 Million Public Offering
September 29 2020 - 9:00PM
Business Wire
Regulatory News:
Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) (“Aptorum
Group” or “Aptorum”), a biopharmaceutical company focused on novel
technologies including the targeting of infectious diseases, today
announced the pricing of a public offering of 2,769,231 Aptorum’s
Class A ordinary shares (or ordinary share equivalents) and
warrants to purchase up to 2,769,231 Class A Ordinary Shares, at a
combined public offering price of $3.25 per share and related
warrant. The warrants have an exercise price of $3.25 per share are
exercisable immediately upon issuance and expire on the five year
anniversary of the date of issuance.
H.C. Wainwright & Co. acted as the exclusive placement agent
for the offering.
The gross proceeds to Aptorum Group from the offering are
expected to be approximately $9.0 million, before deducting the
placement agents’ fees and other estimated offering expenses.
Aptorum Group intends to use the net proceeds from the offering
primarily to conduct further analyses of SACT-1 (a repurposed drug
for neuroblastoma & other solid Tumors) and ALS-4 (a small drug
molecule candidate for Staphylococcus aureus including MRSA), which
are currently on track for IND submission to commence Phase 1b/2a
human clinical trials and undergoing final stages of IND enabling
studies to initiate Phase 1 human clinical trials respectively, and
to accelerate the developments of our pipeline into their
respective clinical phases, as well as for expanding businesses,
working capital and general corporate purposes.
A registration statement on Form F-1 relating to this offering
(file number 333-248743) and an additional registration statement
filed pursuant to Rule 462(b) were declared effective by the
Securities and Exchange Commission (“SEC”) on September 29, 2020.
The offering of the Company’s securities was made only by means of
a prospectus forming a part of the registration statement. The
registration statement on Form F-1 and the final prospectus
relating to the Offering are available on the SEC’s website at
www.sec.gov. Copies of the final prospectus relating to the
offering may be obtained, when available, by contacting H.C.
Wainwright & Co. at 430 Park Avenue, New York, New York 10022,
by telephone: (212) 356-0500, or by email at info@hcwco.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Aptorum Group
Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) is a
pharmaceutical company dedicated to the discovery, development and
commercializing of therapeutic assets to treat diseases with unmet
medical needs, particularly infectious diseases and cancers
(including orphan oncology indications). The pipeline of Aptorum is
also enriched through the establishment of drug discovery platforms
that are meant to enable the discovery of new therapeutics assets
through programs such as the systematic screening of existing
approved drug molecules and microbiome-based research platform for
treatments of metabolic diseases. In addition to the above main
focus, the company is also pursuing therapeutic and diagnostic
projects in neurology, gastroenterology, metabolic disorders,
women’s health and other disease areas. Aptorum also has projects
focused on surgical robotics and natural supplement for women
undergoing menopause and experiencing related symptoms.
For more information about Aptorum Group, please visit
www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release does not constitute an offer to sell or a
solicitation of offers to buy any securities of Aptorum Group.
This press release includes statements concerning Aptorum Group
Limited and its future expectations, plans and prospects that
constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. For this purpose,
any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as “may,” “should,” “expects,” “plans,” “anticipates,”
“could,” “intends,” “target,” “projects,” “contemplates,”
“believes,” “estimates,” “predicts,” “potential,” or “continue,” or
the negative of these terms or other similar expressions. Aptorum
Group has based these forward-looking statements, which include
statements regarding projected timelines for application
submissions and trials, largely on its current expectations and
projections about future events and trends that it believes may
affect its business, financial condition and results of operations.
These forward-looking statements speak only as of the date of this
press release and are subject to a number of risks, uncertainties
and assumptions including, without limitation, risks related to its
announced management and organizational changes, the continued
service and availability of key personnel, its ability to expand
its product assortments by offering additional products for
additional consumer segments, development results, the company’s
anticipated growth strategies, anticipated trends and challenges in
its business, and its expectations regarding, and the stability of,
its supply chain, and the risks more fully described in Aptorum
Group’s Form 20-F and other filings that Aptorum Group may make
with the SEC in the future, as well as the prospectus that received
the French Autorité des Marchés Financiers visa n°20-352 on 16 July
2020.
As a result, the projections included in such forward-looking
statements are subject to change and actual results may differ
materially from those described herein. Aptorum Group assumes no
obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or
otherwise.
This announcement is not a prospectus within the meaning of the
Regulation (EU) n°2017/1129 of 14 June 2017 as amended by
Regulations Delegated (EU) n°2019/980 of 14 March 2019 and
n°2019/979 of 14 March 2019.
This press release is provided “as is” without any
representation or warranty of any kind.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200929006166/en/
Inquiries: Aptorum Group Limited Investor Relations
Department: +44 20 80929299 investor.relations@aptorumgroup.com
Redchip – Financial Communications United States Investor
relations Dave Gentry dave@redchip.com +1 407 491 4498
Actifin – Financial Communications Europe Investor relations
Ghislaine Gasparetto ggasparetto@actifin.fr +33 1 56 88 11 22
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Apr 2023 to Apr 2024